Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Orion Infusions's share price for the quarter that ended in Mar. 2026 was BDT331.4. Orion Infusions's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 20.4 Mil. Therefore, Orion Infusions's market cap for the quarter that ended in Mar. 2026 was BDT6,747.3 Mil.
Orion Infusions's quarterly market cap
declined
from Sep. 2025 (BDT10,766.4 Mil) to Dec. 2025 (BDT6,957.0 Mil) and
declined
from Dec. 2025 (BDT6,957.0 Mil) to Mar. 2026 (BDT6,747.3 Mil).
Orion Infusions's annual market cap
increased
from Jun. 2023 (BDT6,851.1 Mil) to Jun. 2024 (BDT9,783.0 Mil) but then
declined
from Jun. 2024 (BDT9,783.0 Mil) to Jun. 2025 (BDT6,386.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orion Infusions's Enterprise Value for Today is BDT6,210.9 Mil.
Orion Infusions (DHA:ORIONINFU) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orion Infusions Market Cap Related Terms
Orion Infusions Market Cap Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Market Cap distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Orion Infusions's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a Market Cap of BDT5,928.8 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orion Infusions and its competitors. According to the industry distribution chart, Orion Infusions ranks #703 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 68.7%.
Is Orion Infusions' Market Cap too high?
Orion Infusions' current Market Cap is BDT5,928.8 Mil. Based on the distribution chart, Orion Infusions ranks #703 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #703 out of 1024 companies for Market Cap. This places Orion Infusions in the lower half of its industry. The industry median Market Cap is 210.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.88, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Market Cap is BDT5,928.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current Market Cap is BDT5,928.8 Mil. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Market Cap is BDT5,928.8 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
Market Cap: BDT5,928.8 Mil
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
